Home/Pipeline/Avtozma®

Avtozma®

Rheumatoid arthritis

MarketedApproved

Key Facts

Indication
Rheumatoid arthritis
Phase
Marketed
Status
Approved
Company

About Celltrion

Celltrion's mission is to promote patient health by making advanced biologics affordable and accessible globally. It has achieved this by evolving from a contract manufacturer into a vertically integrated powerhouse, becoming the world's leading biosimilar producer with a robust pipeline. Its core strategy leverages massive, FDA/EMA-certified manufacturing capacity, a direct global sales network, and a deep R&D pipeline spanning biosimilars and novel biologics to drive growth and secure long-term market leadership.

View full company profile

Other Rheumatoid arthritis Drugs

DrugCompanyPhase
Early Detection Test for Rheumatoid ArthritisAge LabsDevelopment
Piclidenoson (CF101)Can Fite BiopharmaPhase II/III
ERNA-201Eterna TherapeuticsPreclinical
Tc99m TilmanoceptNavidea BiopharmaceuticalsPhase 2/3
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)LFBPre-clinical
EYD-001 (Takinib analog)EydisBioPreclinical
LFD-200Lifordi ImmunotherapeuticsPhase 1
MEV-N01MesenbioPre-clinical
CIT-013CitryllPhase 2a
Restem-LRestemPhase 2
ASIT PlatformAhead TherapeuticsPre-clinical
AX-158Artax BiopharmaPhase 2